Vimedimex Medi-Pharma JSC (HOSE:VMD)
Vietnam · Delayed Price · Currency is VND 16,450
-950 (-5.46%)
At close: Jan 19, 2026
Vimedimex Medi-Pharma JSC Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | 29,315 | 24,662 | 25,482 | 34,818 | 19,995 | 37,095 | Upgrade |
Depreciation & Amortization | 16,652 | 16,632 | 18,792 | 19,251 | 19,051 | 17,364 | Upgrade |
Other Amortization | 3,006 | 3,006 | 604.9 | - | 369.31 | 321.86 | Upgrade |
Loss (Gain) From Sale of Assets | -9,373 | -7,074 | -15,631 | -7,121 | - | -3,654 | Upgrade |
Loss (Gain) From Sale of Investments | - | - | - | - | -5,531 | - | Upgrade |
Other Operating Activities | 974.83 | 1,160 | 1,431 | -3,364 | -29,865 | 178,445 | Upgrade |
Change in Accounts Receivable | 208,906 | 373,926 | 551,782 | 1,378,506 | 1,182,198 | -445,778 | Upgrade |
Change in Inventory | 103,124 | 169,045 | 698,451 | 1,593,122 | 1,367,202 | 1,083,552 | Upgrade |
Change in Accounts Payable | -144,378 | -461,862 | -1,266,375 | -2,310,209 | -2,979,235 | -710,648 | Upgrade |
Change in Other Net Operating Assets | 4,465 | 4,921 | 7,333 | -2,920 | 3,799 | 6,151 | Upgrade |
Operating Cash Flow | 212,692 | 124,417 | 21,872 | 702,082 | -422,016 | 162,851 | Upgrade |
Operating Cash Flow Growth | - | 468.84% | -96.89% | - | - | 36.98% | Upgrade |
Capital Expenditures | -2,695 | -7,773 | -16,329 | -5,163 | -20,468 | -29,788 | Upgrade |
Sale of Property, Plant & Equipment | - | - | 4.82 | 166.54 | 10.09 | 250 | Upgrade |
Investment in Securities | -208,620 | - | - | -1,380 | - | - | Upgrade |
Other Investing Activities | 5,738 | 6,852 | 11,000 | 6,263 | 14,727 | 3,904 | Upgrade |
Investing Cash Flow | -215,229 | -2,923 | -2,278 | -11,650 | -5,673 | -40,127 | Upgrade |
Short-Term Debt Issued | - | 317,500 | - | - | 1,736,174 | 1,488,835 | Upgrade |
Long-Term Debt Issued | - | - | 338,500 | 634,900 | - | - | Upgrade |
Total Debt Issued | 24,000 | 317,500 | 338,500 | 634,900 | 1,736,174 | 1,488,835 | Upgrade |
Short-Term Debt Repaid | - | -317,500 | - | - | -1,468,800 | -1,447,045 | Upgrade |
Long-Term Debt Repaid | - | - | -338,500 | -1,247,274 | - | - | Upgrade |
Total Debt Repaid | -114,500 | -317,500 | -338,500 | -1,247,274 | -1,468,800 | -1,447,045 | Upgrade |
Net Debt Issued (Repaid) | -90,500 | - | - | -612,374 | 267,374 | 41,790 | Upgrade |
Issuance of Common Stock | - | - | 6,710 | 2,000 | 46,410 | 18,400 | Upgrade |
Common Dividends Paid | -30,178 | -30,178 | -30,178 | -15,116 | -40,067 | -23,603 | Upgrade |
Other Financing Activities | - | - | - | - | 0 | - | Upgrade |
Financing Cash Flow | -120,678 | -30,178 | -23,468 | -625,490 | 273,717 | 36,587 | Upgrade |
Foreign Exchange Rate Adjustments | - | - | - | -12.15 | -0.74 | 5.8 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 0 | 0 | Upgrade |
Net Cash Flow | -123,215 | 91,315 | -3,875 | 64,930 | -153,973 | 159,317 | Upgrade |
Free Cash Flow | 209,998 | 116,644 | 5,543 | 696,919 | -442,484 | 133,063 | Upgrade |
Free Cash Flow Growth | - | 2004.50% | -99.20% | - | - | 342.10% | Upgrade |
Free Cash Flow Margin | 17.90% | 9.34% | 0.16% | 9.85% | -3.59% | 0.73% | Upgrade |
Free Cash Flow Per Share | 13598.43 | 7553.29 | 358.89 | 45136.46 | -28657.78 | 8617.92 | Upgrade |
Cash Interest Paid | 1,421 | 3,703 | 1,749 | 7,612 | 13,200 | 8,150 | Upgrade |
Cash Income Tax Paid | 5,565 | 4,797 | 13,709 | 5,057 | 15,850 | 8,559 | Upgrade |
Levered Free Cash Flow | - | 89,240 | 10,091 | 690,144 | -384,347 | 239,396 | Upgrade |
Unlevered Free Cash Flow | - | 91,554 | 11,184 | 693,335 | -374,507 | 244,221 | Upgrade |
Change in Working Capital | 172,117 | 86,030 | -8,808 | 658,498 | -426,036 | -66,722 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.